For over 60 years, hematopoietic stem cell transplantation has been the major curative
therapy for several hematological and genetic disorders, but its efficacy is limited by the …

The drug named defibrotide (DFT) has been studied for many years. It has been shown to
possess many activities: profibrinolytic, antithrombotic–thrombolytic, antiischemic (heart …

Transplant-associated thrombotic microangiopathy (TMA) leads to generalized endothelial
dysfunction that can progress to multiorgan injury, and severe cases are associated with …

Background The mechanism of kidney injury in hematopoietic stem cell transplantation
(HSCT)–associated thrombotic microangiopathy (TA-TMA) is not completely understood …

Transplant-associated thrombotic microangiopathy (TA-TMA), a complication of
hematopoietic cell transplant (HCT), is associated with significant morbidity and mortality …

Objective To evaluate response rates and survival in adults with transplant‐associated
thrombotic microangiopathy (TA‐TMA) after allogeneic hematopoietic stem cell …

Objective This study aimed to evaluate the effectiveness of Ruxolitinib for acute/chronic graft-
versus-host disease in children. Methods This study was a retrospective trial. We analyzed …

Thrombotic microangiopathy (TMA) is a rare and devastating complication of kidney
transplantation, which often leads to graft failure. Posttransplant TMA (PT-TMA) may occur …

Thrombotic microangiopathy is a potentially lethal complication of haematopoietic stem cell
(bone marrow) transplantation. The pathophysiology is incompletely understood, although …

AKI in the setting of HSCT is commonly investigated among adult patients. In the same way,
malignancies requiring treatment with HSCT are not limited to the adult patient population …